SECOND ADDENDUM TO THE RESEARCH AND LICENSE AGREEMENT
Exhibit 10.6
SECOND ADDENDUM
TO THE RESEARCH AND LICENSE AGREEMENT
This Second Addendum to Research and License Agreement (the “Second Addendum”) is made by and between The Technion Research & Development Foundation Ltd. (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Licensee” or “Eloxx”).
WHEREAS, TRDF and Eloxx are parties to Research and License Agreement with an effective date of August 29th, 2013 (the “License Agreement”), as amended on November 26, 2013, January 14, 2014, June 9, 2014 and August 3, 2014 (collectively, the “Agreement”); and
WHEREAS, the parties desire to continue the relationship contemplated by the Agreement and to further amend the Agreement as set forth herein;
Now, THEREFORE, the parties hereby agree as follows:
| 1. | Unless otherwise defined herein, capitalized terms used in this Second Addendum shall have the meanings assigned thereto in the Agreement. |
| 2. | The Parties agree to add those certain patents and patent applications described in Exhibit A(3) attached hereto, to Exhibits A(1) and A(2) of the Agreement. |
| 3. | Except as added herein, all other terms and conditions of the Agreement shall remain in full force and effect, as relevant to this Second Addendum. |
| 4. | This Second Addendum may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Any signature page delivered by facsimile or electronic image transmission shall be binding to the same extent as an original signature page. |
IN WITNESS WHEREOF, the parties hereby accept and agree to the terms and conditions of this First Addendum.
| ELOXX PHARMACEUTICALS LTD. | THE TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. | |||||||||||
| By: | /s/ Shmuel Tuvia |
By: | /s/ Xxxxxxxx Xxxxxx | |||||||||
| Name: | Shmuel Tuvia | Name: | Xxxxxxxx Xxxxxx | |||||||||
| Title: | COO | Title: | Technology Transfer Office, Manager | |||||||||
| Date: | Jan. 21, 2015 | Date: | ||||||||||
Exhibit A(3)
| USE OF AMINOGLYCOSIDE ANALOGS IN THE TREATMENT OF RETT SYNDROME | ||||||||||||||
| Our Ref Client Ref |
Country | Earliest Priority |
Entry Date |
Filing Date Application No. |
Issue Date Patent No. |
Status | Assignee | |||||||
| 59529 ? |
USA PRO |
05-Jun-2014 62/006,028 |
Filed | Technion Research & Development Foundation Limited ; Eloxx Pharmaceuticals Ltd. | ||||||||||
| PatentNum |
PatentName | PatentStatus Desc |
ApplicationDate | ApplicationNum | CountryDesc | Patent Date |
PatentNo | PublicationDate | PublicationNum | |||||||||||||||||||||
| 0816 |
NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | NP from PCT | N/A | |||||||||||||||||||||||||||
| 0816-00 |
REDESIGN OF AMINOGLYCOSIDES FOR TREATMENT OF HUMAN GENETIC DISEASES CAUSED BY PREMATURE STOP MUTATIONS | Expired | 03/04/2006 | 60/788,070 | Xxxxxx Xxxxxx | |||||||||||||||||||||||||
| 0000-00 |
NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | Expired | 10/04/2007 | PCT/IL/2007/000463 | PCT | 11/10/2007 | WO 2007/113841 | |||||||||||||||||||||||
| 0819-02 |
NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | Filed | 25/09/2008 | 000000 | Xxxxxx | |||||||||||||||||||||||||
| 0816-03 |
NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | Filed | 25/09/2008 | 2,646,407 | Canada | |||||||||||||||||||||||||
| 0816-04 |
NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | Filed | 10/04/2007 | 07736203.6 | Europe | |||||||||||||||||||||||||
| 0816-05 |
NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | Filed | 03/10/2008 | 2009-503741 | Japan | 10/09/2009 | 2009-532461 | |||||||||||||||||||||||
| 0816-06 |
NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | Filed | 01/10/2008 | 12/285,299 | United Slates | |||||||||||||||||||||||||
| 0816-07 |
NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | Filed | 31/10/2008 | 00000/XXXXX/0000 | Xxxxx | |||||||||||||||||||||||||
| 0816-08 |
NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | Filed | 10/04/2007 | 11173958.7 | Europe | 30/11/2011 | 2390255 | |||||||||||||||||||||||
| PatentNum | PatentName | PatentStatusDesc | Application Date |
ApplicationNum | CountryDesc | PatentDate | PatentNo | PublicationDate | PublicationNum | |||||||||||||||||||||
| 1302 |
REPAIRING FAULTY GENES BY AMINOGLYCOSIDES: IDENTIFICATION OF NEW PHARMACOPHORE WITH ENHANCED SUPPRESSION OF DI | NP from PCT | N/A | |||||||||||||||||||||||||||
| 1302-00 |
REPAIRING FAULTY GENES BY AMINOGLYCOSIDES: IDENTIFICATION OF NEW PHARMACOPHORE WITH ENHANCED SUPPRESSION OF DI | Expired | 18/11/2010 | 61/414,956 | United States | |||||||||||||||||||||||||
| 1302-01 |
AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS | Expired | 17/11/2011 | PCT/IL/2011/000889 | PCT | 24/05/2012 | WO2012/066546 | |||||||||||||||||||||||
| 1302-02 |
AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS | Filed | 16/05/2013 | 13/885,715 | Xxxxxx Xxxxxx | |||||||||||||||||||||||||
| 0000-00 |
AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS | Filed | 17/11/2011 | 11799501.9 | Europe | |||||||||||||||||||||||||
| 1302-04 |
AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS | Filed | 20/05/2013 | Japan | ||||||||||||||||||||||||||
| 1302-05 |
AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS | Filed | 02/05/2013 | 2,816,789 | Canada | |||||||||||||||||||||||||
| 1302-06 |
AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS | Filed | 07/05/2013 | 876/MUMNP/2013 | India | |||||||||||||||||||||||||
| 1302-07 |
AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS | Filed | 16/05/2013 | 000000 | Xxxxxx | . | ||||||||||||||||||||||||
